AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31774032 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-linear amplification configurations
Number of subjects: 30
Study 31774032 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel feature in wireless microphone systems
Number of subjects: 30
Study 31774032 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal-hearing listeners)
Number of subjects: 30
Study 31774125 — intervention group
Group type: EXPERIMENTAL
Intervention: Total 25-hydroxyvitamin D (t25-OHD)
Number of subjects: 203
Study 31774125 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,25(OH)2D
Number of subjects: 203
Study 31774125 — intervention group
Group type: EXPERIMENTAL
Intervention: Calculated free 25-hydroxyvitamin D (cf25-OHD)
Number of subjects: 203
Study 31774125 — intervention group
Group type: EXPERIMENTAL
Intervention: Directly measured free 25-hydroxyvitamin D (dmf25-OHD)
Number of subjects: 203
Study 31774125 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 203
Study 31774125 — intervention group
Group type: EXPERIMENTAL
Intervention: Parathyroid hormone (PTH)
Number of subjects: 203
Study 31774125 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting insulin and HOMA-IR
Number of subjects: 203
Study 31774522 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (1200 mg/m2, later amended to 1000 mg/m2 on days 1 and 8 every 3 weeks), plus trastuzumab (8-mg/kg loading dose, then 6 mg/kg), and pertuzumab (840-mg loading dose, then 420 mg) once every 3 weeks.
Number of subjects: 45
Study 31774688 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks for up to 35 cycles
Number of subjects: 258
Study 31774916 — intervention group
Group type: EXPERIMENTAL
Intervention: VARIZIG (≤125 IU/10 kg)
Number of subjects: 123
Study 31774957 — intervention group
Group type: EXPERIMENTAL
Intervention: Low C-PTP and d-dimer <1000 ng/mL
Number of subjects: 2017
Study 31774957 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate C-PTP and d-dimer <500 ng/mL
Number of subjects: 2017
Study 31774957 — intervention group
Group type: EXPERIMENTAL
Intervention: d-dimer level 500 to 999 ng/mL
Number of subjects: 2017
Study 31774957 — intervention group
Group type: COMPARATOR
Intervention: No diagnosis of pulmonary embolism and no anticoagulant therapy
Number of subjects: 2017
Study 31774957 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic strategy with low C-PTP and d-dimer <1000 ng/mL
Number of subjects: 2017
Study 31774957 — intervention group
Group type: COMPARATOR
Intervention: Alternative strategy with low C-PTP and d-dimer <500 ng/mL
Number of subjects: 2017
Study 31775667 — intervention group
Group type: EXPERIMENTAL
Intervention: Appendicular lean mass measured by dual-energy X-ray absorptiometry (DXA)
Number of subjects: 0
Study 31775667 — intervention group
Group type: COMPARATOR
Intervention: Grade 3 to 5 chemotherapy-related toxicities
Number of subjects: 0
Study 31775677 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (600 mg) followed by misoprostol (400 μg, two doses 4 hrs apart)
Number of subjects: 464
Study 31775677 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol alone (400 μg, two doses 4 hrs apart)
Number of subjects: 464
Study 31775677 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone and misoprostol
Number of subjects: 464
Study 31775677 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol alone
Number of subjects: 464
Study 31775708 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary hypertension (PH) group
Number of subjects: 51
Study 31775708 — intervention group
Group type: COMPARATOR
Intervention: Non-PH group
Number of subjects: 51
Study 31775708 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 51
Study 31775714 — intervention group
Group type: EXPERIMENTAL
Intervention: Leisure-time physical activity (median 12.0 MET-hours/week)
Number of subjects: 602
Study 31775714 — intervention group
Group type: EXPERIMENTAL
Intervention: Work-related physical activity (median 14.0 MET-hours/week)
Number of subjects: 602
Study 31775714 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary time
Number of subjects: 602
Study 31775838 — intervention group
Group type: EXPERIMENTAL
Intervention: Transabdominal intestinal ultrasonography
Number of subjects: 116
Study 31776238 — intervention group
Group type: EXPERIMENTAL
Intervention: CRS patients without nasal polyps
Number of subjects: 290
Study 31776238 — intervention group
Group type: EXPERIMENTAL
Intervention: CRS patients with nasal polyps
Number of subjects: 290
Study 31776238 — intervention group
Group type: EXPERIMENTAL
Intervention: CRS patients
Number of subjects: 290
Study 31776238 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 290
Study 31776631 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemokine receptor-4 targeted PET/CT
Number of subjects: 30
Study 31776899 — intervention group
Group type: EXPERIMENTAL
Intervention: INC280 (300 mg twice daily) + buparlisib (80 mg once daily)
Number of subjects: 43
Study 31776899 — intervention group
Group type: COMPARATOR
Intervention: INC280 (monotherapy)
Number of subjects: 43
Study 31777470 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR) in patients with coronary cusp fusion (27 patients)
Number of subjects: 71
Study 31777470 — intervention group
Group type: COMPARATOR
Intervention: Transcatheter aortic valve replacement (TAVR) in patients with mixed cusp fusion (44 patients)
Number of subjects: 71
Study 31777761 — intervention group
Group type: EXPERIMENTAL
Intervention: Asoprisnil 10 mg
Number of subjects: 0
Study 31777761 — intervention group
Group type: EXPERIMENTAL
Intervention: Asoprisnil 25 mg
Number of subjects: 0
Study 31777761 — intervention group
Group type: EXPERIMENTAL
Intervention: Asoprisnil (both dosages)
Number of subjects: 0
Study 31777783 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID
Number of subjects: 4967
Study 31777783 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID
Number of subjects: 4967
Study 31777783 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib monotherapy
Number of subjects: 4967
Study 31777783 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib (overall)
Number of subjects: 4967
Study 31777783 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline factors
Number of subjects: 4967
Study 31778074 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib (ALK, MET & ROS1 inhibitor)
Number of subjects: 0
Study 31778266 — intervention group
Group type: EXPERIMENTAL
Intervention: Serratus anterior plane block (SAPB)
Number of subjects: 146
Study 31778266 — intervention group
Group type: COMPARATOR
Intervention: Control (standard local anesthesia and sedation)
Number of subjects: 146
Study 31778267 — intervention group
Group type: EXPERIMENTAL
Intervention: Capmatinib 600 mg bid capsules
Number of subjects: 0
Study 31778267 — intervention group
Group type: EXPERIMENTAL
Intervention: Capmatinib 400 mg bid tablets
Number of subjects: 0
Study 31778267 — intervention group
Group type: EXPERIMENTAL
Intervention: Capmatinib 200 mg bid, 250 mg bid, and 450 mg bid capsules
Number of subjects: 0
Study 31778267 — intervention group
Group type: EXPERIMENTAL
Intervention: Capmatinib 400 mg bid tablets/600 mg bid capsules
Number of subjects: 0
Study 31778281 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain EASE program (internet-delivered self-management program based on cognitive behavioral therapy)
Number of subjects: 58
Study 31778281 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain EASE program
Number of subjects: 58
Study 31778283 — intervention group
Group type: EXPERIMENTAL
Intervention: SHP656 (polysialylated recombinant factor VIII)
Number of subjects: 40
Study 31778283 — intervention group
Group type: COMPARATOR
Intervention: rFVIII (octocog alfa)
Number of subjects: 40
Study 31778781 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD probands
Number of subjects: 217
Study 31778781 — intervention group
Group type: EXPERIMENTAL
Intervention: Unaffected siblings
Number of subjects: 217
Study 31778781 — intervention group
Group type: COMPARATOR
Intervention: Typically developing youths
Number of subjects: 217
Study 31778781 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD probands and unaffected siblings
Number of subjects: 217
Study 31778798 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceritinib (750 mg/day, fasted)
Number of subjects: 124
Study 31779476 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitor with Remote Monitoring
Number of subjects: 0
Study 31779517 — intervention group
Group type: EXPERIMENTAL
Intervention: Centralized Direct-Mail Colorectal Cancer Screening Approach
Number of subjects: 0
Study 31779517 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 31779564 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 5005
Study 31779699 — intervention group
Group type: EXPERIMENTAL
Intervention: DynaMesh®-Parastomal (intra-abdominal onlay mesh)
Number of subjects: 204
Study 31779699 — intervention group
Group type: COMPARATOR
Intervention: Conventional colostomy without mesh
Number of subjects: 204
Study 31779864 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 2997
Study 31779926 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 1846
Study 31779926 — intervention group
Group type: EXPERIMENTAL
Intervention: Other medications
Number of subjects: 1846
Study 31779926 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity analysis (n=1,439)
Number of subjects: 1846
Study 31779928 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 2331
Study 31779928 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 2331
Study 31779928 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative comorbidity score
Number of subjects: 2331
Study 31779928 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary composite endpoint (all-cause mortality or hospitalization)
Number of subjects: 2331
Study 31780140 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication-related adverse events (MRE) in anaesthesia care
Number of subjects: 7072
Study 31780140 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasoconstrictor agents, benzodiazepines, and neuromuscular blocking agents
Number of subjects: 7072
Study 31780140 — intervention group
Group type: EXPERIMENTAL
Intervention: Local corrective patient safety and quality improvement measures
Number of subjects: 7072
Study 31780237 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG)
Number of subjects: 65
Study 31780237 — intervention group
Group type: COMPARATOR
Intervention: Tc
Number of subjects: 65
Study 31780255 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab (15 mg/kg for patients <18 years, 1200 mg for patients 18-29 years)
Number of subjects: 90
Study 31780963 — intervention group
Group type: EXPERIMENTAL
Intervention: Kundalini Yoga Meditation
Number of subjects: 0
Study 31780963 — intervention group
Group type: COMPARATOR
Intervention: Relaxation Response Meditation
Number of subjects: 0
Study 31780970 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 0
Study 31780970 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study 31781021 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 31781386 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-energy X-ray absorptiometry (DXA)
Number of subjects: 61
Study 31781386 — intervention group
Group type: COMPARATOR
Intervention: MRI
Number of subjects: 61
Study 31781386 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (exercise and/or nutrition)
Number of subjects: 61
Study 31781889 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress group (SG) with PSS-10 ≥ 19
Number of subjects: 110
Study 31781889 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) with PSS-10 < 19
Number of subjects: 110
Study 31781957 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary behavior (15 MET-h/week)
Number of subjects: 189
Study 31781957 — intervention group
Group type: EXPERIMENTAL
Intervention: Total physical activity (148 MET-h/week)
Number of subjects: 189
Study 31781957 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure
Number of subjects: 189
Study 31781957 — intervention group
Group type: EXPERIMENTAL
Intervention: Nulliparity
Number of subjects: 189
Study 31781957 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary behavior as a predictor of preeclampsia
Number of subjects: 189
Study 31781957 — intervention group
Group type: EXPERIMENTAL
Intervention: Total physical activity and sedentary behavior
Number of subjects: 189
Study 31782492 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish intake
Number of subjects: 4680
Study 31782492 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary TMAO
Number of subjects: 4680
Study 31783178 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of ALK translocation by FISH
Number of subjects: 32
Study 31783178 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemistry
Number of subjects: 32
Study 31783178 — intervention group
Group type: EXPERIMENTAL
Intervention: RNA sequencing
Number of subjects: 32
Study 31783773 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol serum levels ≥ 20 mg/L
Number of subjects: 268
Study 31783773 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol serum levels > 40 mg/L
Number of subjects: 268
Study 31783773 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-drug antibodies detected in serum samples
Number of subjects: 268
Study 31783791 — intervention group
Group type: EXPERIMENTAL
Intervention: ST elevation myocardial infarction (STEMI) management and outcomes
Number of subjects: 5479
Study 31783816 — intervention group
Group type: EXPERIMENTAL
Intervention: Precision radiotherapy (volumetric modulated arc therapy or stereotactic body radiotherapy) with 18 × 2.33Gy in 3.5 weeks
Number of subjects: 65
Study 31783816 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy with 10x3Gy in 2 weeks
Number of subjects: 65
Study 31783832 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral health risk factor screening and brief intervention targeting two or more HRFs
Number of subjects: 6251
Study 31783832 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral health risk factor profiles including overweight, alcohol, and/or smoking
Number of subjects: 6251
Study 31783832 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions targeting two or more HRFs
Number of subjects: 6251
Study 31784451 — intervention group
Group type: EXPERIMENTAL
Intervention: r-axSpA
Number of subjects: 669
Study 31784451 — intervention group
Group type: COMPARATOR
Intervention: nr-axSpA
Number of subjects: 669
Study 31784451 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 669
Study 31784744 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal menstruation
Number of subjects: 82
Study 31784744 — intervention group
Group type: EXPERIMENTAL
Intervention: Irregular menstruation/menopause
Number of subjects: 82
Study 31784744 — intervention group
Group type: EXPERIMENTAL
Intervention: Perimenstrual/menopausal phenotype
Number of subjects: 82
Study 31784744 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 82
Study 31784744 — intervention group
Group type: COMPARATOR
Intervention: Gene microarray data (n = 53)
Number of subjects: 82
Study 31784744 — intervention group
Group type: COMPARATOR
Intervention: Fat cell size
Number of subjects: 82
Study 31784934 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (patients with adenomatous polyps of the colon and yang-deficiency constitution)
Number of subjects: 119
Study 31784934 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients without colon polyps and with balanced constitution)
Number of subjects: 119
Study 31784934 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 119
Study 31785185 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes (Multidimensional Fatigue Inventory, patient global assessment of disease activity [PtGA], Short Form 36 health survey [SF-36], Brief Illness Perception Questionnaire)
Number of subjects: 112
Study 31785185 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician global assessment of disease activity (PhGA)
Number of subjects: 112
Study 31785185 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory outcomes (C-reactive protein [CRP] level, erythrocyte sedimentation rate [ESR])
Number of subjects: 112
Study 31785185 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaging outcomes (PETVAS, a qualitative score of vascular involvement)
Number of subjects: 112
Study 31785259 — intervention group
Group type: EXPERIMENTAL
Intervention: Total hyocholic acid (HCA)
Number of subjects: 205
Study 31785259 — intervention group
Group type: EXPERIMENTAL
Intervention: Total HCA/total chenodeoxycholic acid (CDCA) ratio
Number of subjects: 205
Study 31785259 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting plasma BAs
Number of subjects: 205
Study 31785259 — intervention group
Group type: EXPERIMENTAL
Intervention: 6α-hydroxylated BAs
Number of subjects: 205
Study 31785337 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiation therapy (RT) to at-risk areas in the involved neck (60-66 Gy) and uninvolved neck (54 Gy)
Number of subjects: 60
Study 31785337 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative RT avoiding the resected primary tumor site
Number of subjects: 60
Study 31785337 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeding tube dependence rates during and after RT
Number of subjects: 60
Study 31785503 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment (monotherapy or combination therapy)
Number of subjects: 249
Study 31785703 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia
Number of subjects: 0
Study 31785703 — intervention group
Group type: COMPARATOR
Intervention: Procedural sedation
Number of subjects: 0
Study 31785831 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal autologous adipose tissue-derived mesenchymal stem cells (AD-MSCs) - 100 million cells infused after a standard lumbar puncture at the L3-4 level, administered 11 months after injury.
Number of subjects: 1
Study 31785831 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal autologous adipose tissue-derived mesenchymal stem cells (AD-MSCs)
Number of subjects: 1
Study 31786043 — intervention group
Group type: EXPERIMENTAL
Intervention: On-hour admission
Number of subjects: 1269
Study 31786043 — intervention group
Group type: COMPARATOR
Intervention: Off-hour admission
Number of subjects: 1269
Study 31786043 — intervention group
Group type: EXPERIMENTAL
Intervention: On-hour admission without neurosurgical interventions
Number of subjects: 1269
Study 31786043 — intervention group
Group type: EXPERIMENTAL
Intervention: On-hour admission without hematoma evacuation surgery
Number of subjects: 1269
Study 31786124 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery alone
Number of subjects: 529
Study 31786124 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (55.8 Gy)
Number of subjects: 529
Study 31786124 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (chemotherapy and 55.8 Gy radiotherapy)
Number of subjects: 529
Study 31786124 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy (chemotherapy and 45 Gy radiotherapy, then surgery and radiotherapy boost)
Number of subjects: 529
Study 31786235 — intervention group
Group type: EXPERIMENTAL
Intervention: CTV registration
Number of subjects: 56
Study 31786235 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone registration
Number of subjects: 56
Study 31786235 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragm registration
Number of subjects: 56
Study 31786235 — intervention group
Group type: EXPERIMENTAL
Intervention: Average peak-to-peak respiratory tumor motion
Number of subjects: 56
Study 31786235 — intervention group
Group type: EXPERIMENTAL
Intervention: General findings
Number of subjects: 56
Study 31786235 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendation
Number of subjects: 56
Study 31786276 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy (IMRT) using a simultaneous integrated boost technique (60 Gy high dose and 54 Gy low dose in 30 fractions)
Number of subjects: 53
Study 31786276 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy (IMRT)
Number of subjects: 53
Study 31786971 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure ≥180 mm Hg
Number of subjects: 300193
Study 31786971 — intervention group
Group type: COMPARATOR
Intervention: Normal blood pressure levels
Number of subjects: 300193
Study 31786971 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure grade 1
Number of subjects: 300193
Study 31786971 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure grade 2
Number of subjects: 300193
Study 31786971 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure grade 3
Number of subjects: 300193
Study 31786971 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for ASCVD
Number of subjects: 300193
Study 31786971 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for ASCVD
Number of subjects: 300193
Study 31787498 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) glibenclamide (BIIB093; glyburide) treatment
Number of subjects: 83
Study 31787498 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission NIHSS
Number of subjects: 83
Study 31787498 — intervention group
Group type: EXPERIMENTAL
Intervention: ACA territory infarct volume
Number of subjects: 83
Study 31787498 — intervention group
Group type: EXPERIMENTAL
Intervention: Infarct lesions involving the anterior cerebral artery (ACA) territory and its middle cerebral artery (MCA) border zone
Number of subjects: 83
Study 31787498 — intervention group
Group type: EXPERIMENTAL
Intervention: Left MCA infarcts
Number of subjects: 83
Study 31787527 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative sensory testing (QST) assessments including cold pressor test, conditioned pain modulation paradigm, repetitive pin-prick stimuli, and pressure stimulation.
Number of subjects: 182
Study 31787527 — intervention group
Group type: COMPARATOR
Intervention: Quantitative sensory testing (QST) assessments in patients with CP.
Number of subjects: 182